Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Monday 04 March, 2019

Verseon Corporation

Additional Listing & Total Voting Rights

RNS Number : 6720R
Verseon Corporation
04 March 2019
 

March 4, 2019

 

Verseon Corporation

 

("Verseon" or the "Company")

 

Additional Listing & Total Voting Rights

 

Fremont, Calif.-Verseon, a technology-based pharmaceutical company, announces that application has been made for 4,375 new shares of common stock ("Common Shares") of par value $0.001 each to be admitted to trading on AIM pursuant to regularly scheduled vesting of restricted stock units (the "Issuance").

The 4,375 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on March 7, 2019 ("Admission").

 

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,699,413 Common Shares and the Company will hold 42,917 shares in treasury. Therefore, the total number of Common Shares in the Company with voting rights will be 151,656,496. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.  

 

Other Information

Further to the announcement of November 6, 2018, Verseon also confirms the completion of normal and customary regulatory diligence on Sangtae Kim, a non-executive director of the Company. In relation to Mr. Kim's appointment, the following information is disclosed pursuant to Schedule 2, paragraph (g) of the AIM Rules for Companies:

 

Full Name:

Sangtae Kim

Age:

60

Current Directorships /
Partnership:

Purdue University

Previous Directorships /
Partnership in the past 5 years:

Prowd Sciences Inc.

The Morgridge Institute for Research Inc.

 

Shareholding in the Company:

Nil

 

- Ends -

 

For further information, please contact:

 

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000


 

Arden Partners (NOMAD and Joint Broker)

 

Ruari McGirr / Ciaran Walsh / Alex Penney

 +44 (0) 20 7614 5900


 

Cantor Fitzgerald Europe (Joint Broker) 

 

Phil Davies

+44 (0) 20 7894 7000

 

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers)

 

Henry Harrison-Topham / Jamie Hooper

+44 (0) 20 7466 5000

 

For trade and pharma media enquiries, please contact

Vane Percy & Roberts

 

Simon Vane Percy

+44 (0) 1737 821 890

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSJJMFTMBMMBBL

a d v e r t i s e m e n t